^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Beta radiation emitter

    Related drugs:
    22h
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=138, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2028 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    5d
    Preclinical and First-in-Human Study of Carbonic Anhydrase IX-Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma. (PubMed, J Nucl Med)
    This is early evidence that the CAIX-targeting theranostic pair [68Ga]Ga/[177Lu]Lu-NYM096 is feasible, offering a strategy for patients with end-stage ccRCC. The gastric toxicity proposes a significant challenge for CAIX-targeting radiopharmaceutical therapy.
    P1 data • Preclinical • Journal • First-in-human
    |
    CA9 (Carbonic anhydrase 9)
    5d
    A Study of LY4257496 in Participants With Cancer (OMNIRAY) (clinicaltrials.gov)
    P1, N=421, Recruiting, Eli Lilly and Company
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    capecitabine • fulvestrant
    6d
    NETTER-3: Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (clinicaltrials.gov)
    P3, N=240, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Sep 2030 --> Dec 2028
    Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    Lutathera (lutetium Lu 177 dotatate) • octreotide acetate
    6d
    177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia (clinicaltrials.gov)
    P2, N=40, Suspended, M.D. Anderson Cancer Center | Initiation date: Dec 2025 --> Aug 2025 | Recruiting --> Suspended
    Trial initiation date • Trial suspension
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    7d
    Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial (clinicaltrials.gov)
    P2, N=100, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    |
    sunitinib • everolimus • Cabometyx (cabozantinib tablet) • Lutathera (lutetium Lu 177 dotatate)
    8d
    LuPARP: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (clinicaltrials.gov)
    P1, N=18, Completed, Vastra Gotaland Region | Active, not recruiting --> Completed
    Trial completion
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
    8d
    Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Fundación de investigación HM | Phase classification: P2 --> P1/2
    Phase classification
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
    9d
    The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu-DOTA-TATE: A post-authorisation safety study. (PubMed, J Neuroendocrinol)
    Trial registration: EudraCT, 2019-004073-76. Registered 20/08/2020.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lutathera (lutetium Lu 177 dotatate)
    9d
    Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors (clinicaltrials.gov)
    P1/2, N=65, Recruiting, Nationwide Children's Hospital | Trial completion date: Nov 2027 --> Nov 2033 | Trial primary completion date: Nov 2027 --> Nov 2028
    Trial completion date • Trial primary completion date
    |
    Lutathera (lutetium Lu 177 dotatate)
    14d
    A sstR2-targeted radiohybrid theranostic agent for PET imaging and β- therapy with excellent preclinical performance. (PubMed, Npj Imaging)
    The rh-theranostic agent demonstrates similar in vitro behavior compared to the gold standards [177Lu]Lu-DOTA-TATE and SiFAlin-TATE, along with an exceptionally high tumor uptake (53.58 ± 5.51% ID/g for the radiofluorinated version) after 1 h post-injection in AR42J tumor-bearing mice, making it ideal for imaging. Moreover, clearance from normal tissues and considerable tumor retention (10.32 ± 7.04%ID/g) for [177Lu]Lu-TATE4 were observed at 24 p.i., suggesting good therapeutic applicability.
    Preclinical • Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Lutathera (lutetium Lu 177 dotatate)
    14d
    177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=55, Active, not recruiting, Weill Medical College of Cornell University | Trial completion date: May 2026 --> Sep 2026
    Trial completion date
    |
    177Lu-rosopatamab tetraxetan (TLX591)